Related Experiment Video

Updated: Jul 9, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

[mTOR signal pathway and its inhibitors in antitumor therapy: a review]

Jia-Jia Huang1, Tong-Yu Lin

  • 1State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.

AI Zheng = Aizheng = Chinese Journal of Cancer
|December 14, 2007
PubMed

Insights

Mammalian target of rapamycin (mTOR) regulates cell growth and is often hyperactive in cancers. mTOR-targeted therapies show promise for managing various carcinomas by inhibiting this pathway.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Mammalian target of rapamycin (mTOR) is a critical signaling molecule in the PI3K/Akt pathway.
  • mTOR integrates signals related to growth factors, nutrients, and cellular energy.
  • Aberrant mTOR pathway hyperactivity is frequently observed in various carcinomas due to gene mutations.

Purpose of the Study:

  • To review the current research status of mTOR and its inhibitors in antitumor therapy.
  • To highlight the significance of mTOR pathway dysregulation in cancer development.
  • To discuss the therapeutic potential of targeting mTOR in cancer management.

Main Methods:

  • Literature review of scientific articles and research studies.
  • Analysis of the role of mTOR in cell growth, proliferation, and cancer.
  • Examination of the mechanisms and efficacy of mTOR inhibitors in preclinical and clinical settings.

Main Results:

  • mTOR pathway hyperactivity is a common hallmark of many cancers.
  • mTOR inhibitors have demonstrated significant potential in preclinical and clinical antitumor studies.
  • Targeting mTOR offers a promising strategy for the management of diverse types of cancer.

Conclusions:

  • The mTOR pathway is a crucial regulator of cell metabolism and growth, frequently dysregulated in cancer.
  • mTOR-targeted therapies represent a significant advancement in cancer treatment strategies.
  • Further research into mTOR inhibitors could lead to more effective cancer therapies.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...